187 related articles for article (PubMed ID: 21738089)
1. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans.
Meyer CH; Krohne TU; Holz FG
Retina; 2011 Oct; 31(9):1877-84. PubMed ID: 21738089
[TBL] [Abstract][Full Text] [Related]
2. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans.
Meyer CH; Krohne TU; Holz FG
Acta Ophthalmol; 2012 Feb; 90(1):68-70. PubMed ID: 20163369
[TBL] [Abstract][Full Text] [Related]
3. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
Krohne TU; Eter N; Holz FG; Meyer CH
Am J Ophthalmol; 2008 Oct; 146(4):508-12. PubMed ID: 18635152
[TBL] [Abstract][Full Text] [Related]
4. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans.
Krohne TU; Liu Z; Holz FG; Meyer CH
Am J Ophthalmol; 2012 Oct; 154(4):682-686.e2. PubMed ID: 22818800
[TBL] [Abstract][Full Text] [Related]
5. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors.
Krohne TU; Muether PS; Stratmann NK; Holz FG; Kirchhof B; Meyer CH; Fauser S
Retina; 2015 Jan; 35(1):69-74. PubMed ID: 25077535
[TBL] [Abstract][Full Text] [Related]
6. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys.
Kakinoki M; Sawada O; Sawada T; Saishin Y; Kawamura H; Ohji M
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5877-80. PubMed ID: 22836776
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.
Roh MI; Kim HS; Song JH; Lim JB; Kwon OW
Ophthalmology; 2009 Jan; 116(1):80-6. PubMed ID: 19118699
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
Miyake T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ogasawara K; Ohji M
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
[TBL] [Abstract][Full Text] [Related]
9. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
[TBL] [Abstract][Full Text] [Related]
10. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.
Beer PM; Bakri SJ; Singh RJ; Liu W; Peters GB; Miller M
Ophthalmology; 2003 Apr; 110(4):681-6. PubMed ID: 12689886
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
12. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
Matsuyama K; Ogata N; Matsuoka M; Wada M; Nishimura T; Takahashi K
J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
[TBL] [Abstract][Full Text] [Related]
13. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
dell'Omo R; Cassetta M; dell'Omo E; di Salvatore A; Hughes JM; Aceto F; Porcellini A; Costagliola C
Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
15. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection.
Agawa T; Usui Y; Wakabayashi Y; Okunuki Y; Juan M; Umazume K; Kezuka T; Takeuchi M; Yamauchi Y; Goto H
Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651
[TBL] [Abstract][Full Text] [Related]
16. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E
Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of intravitreal bevacizumab (Avastin).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Singh RJ
Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery.
Takamura Y; Kubo E; Akagi Y
Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
